Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1
By: Andres Rosende, Cesar Romero, Donald J. DiPette, Jeffrey Brettler, Patrick Van der Stuyft, Gautam Satheesh, Pablo Perel, Niamh Chapman, Andrew E. Moran, Aletta E. Schutte, James E. Sharman, Vilma Irazola, Mark D. Huffman, Norm R. C. Campbell, Abdul Salam, Fernando Lanas, Antonio Coca, Sebastian Garcia-Zamora, Alejandro Ferreiro, Patricio Lopez-Jaramillo, Jorge Rico-Fontalvo, Emily Ridley, Dean Picone, David Flood, Daniel José Piñeiro, Carolina Neira Ojeda, Gonzalo Rodriguez, Irmgardt A. Wellmann, Marcelo Orias, Marcela Rivera, Matías Villatoro Reyes, Oyere Onuma, Shaun Ramroop, Taskeen Khan, Yamile Valdes Gonzalez, Weimar Kunz Sebba Barroso, Frida L. Plavnik, Eric Zuniga, Ana María Grassani, Carlos Tajer, Ezequiel Zaidel, Marcos J. Marin, Shana Cyr-Philbert, Ignacio Amorin, Miguel Angel Diaz Aguilera, Luiz Bortolotto, Alvaro Avezum, Antonio Luiz P. Ribeiro, Sheldon Tobe, Teresa Aumala, Sonia Angell, Pablo Lavados, Sheila Ouriques Martins, Ana Munera Echeverri, Marc G. Jaffe, Dorairaj Prabhakaran, Gianfranco Parati, Xin Hua Zhang, Anthony Rodgers, Salim Yusuf, Paul K. Whelton and Pedro Ordunez
References
- Khan T, Moran AE, Perel P, Whelton PK, Brainin M, Feigin V, et al. The HEARTS partner forum-supporting implementation of HEARTS to treat and control hypertension. Front Public Health. 2023;24(11):1146441. DOI: 10.3389/fpubh.2023.1146441
- Ordunez P, Campbell NRC, DiPette DJ, Jaffe MG, Rosende A, Martinez R, et al. HEARTS in the Americas: Targeting health system change to improve population hypertension control. Curr Hypertens Rep. 2024;26(4):141–156. DOI: 10.1007/s11906-023-01286-w
- Moran AE, Gupta R, Global Hearts Initiative Collaborators. Implementation of Global Hearts Hypertension Control Programs in 32 low- and middle-income countries: JACC International. J Am Coll Cardiol. 2023;82(19):1868–1884. DOI: 10.1016/j.jacc.2023.08.043
- Martinez R, Soliz P, Campbell NRC, Lackland DT, Whelton PK, Ordunez P. Association between population hypertension control and ischemic heart disease and stroke mortality in 36 countries of the Americas, 1990–2019: An ecological study. Rev Panam Salud Publica. 2022;46:
e143 . DOI: 10.26633/RPSP.2022.143 - Rosende A, DiPette D, Brettler J, Rodríguez G, Zuniga E, Connell K, et al. HEARTS in the Americas appraisal checklist and clinical pathway for comprehensive hypertension management in primary care. Rev Panam Salud Publica. 2022;2(46):
e125 . DOI: 10.26633/RPSP.2022.125 - Campbell NRC, Paccot Burnens M, Whelton PK, Angell SY, Jaffe MG, Cohn J, et al. 2021 World Health Organization guideline on pharmacological treatment of hypertension: Policy implications for the region of the Americas. Lancet Reg Health Am. 2022;9. DOI: 10.1016/j.lana.2022.100219
- Brettler JW, Arcila GPG, Aumala T, Best A, Campbell NR, Cyr S, et al. Drivers and scorecards to improve hypertension control in primary care practice: Recommendations from the HEARTS in the Americas Innovation Group. Lancet Reg Health Am. 2022 May;9. DOI: 10.1016/j.lana.2022.100223
- DiPette DJ, Goughnour K, Zuniga E, Skeete J, Ridley E, Angell S, et al. Standardized treatment to improve hypertension control in primary health care: the HEARTS in the Americas initiative. J Clin Hypertens. 2020;22(12):2285–2295. DOI: 10.1111/jch.14072
- DiPette DJ, Skeete J, Ridley E, Campbell NRC, Lopez-Jaramillo P, Kishore SP, et al. Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications. J Clin Hypertens (Greenwich). 2019;21(1):4–15. DOI: 10.1111/jch.13426
- Ordunez P, Tajer C, Gaziano T, Rodriguez YA, Rosende A, Jaffe MG. The HEARTS app: A clinical tool for cardiovascular risk and hypertension management in primary health care. Rev Panam Salud Publica. 2022;28(46):
e12 . DOI: 10.26633/RPSP.2022.12 - Rosende A, DiPette DJ, Martinez R, Brettler JW, Rodriguez G, Zuniga E, et al. HEARTS in the Americas clinical pathway. Strengthening the decision support system to improve hypertension and cardiovascular disease risk management in primary care settings. Front Cardiovasc Med. 2023;10:
1102482 . DOI: 10.3389/fcvm.2023.1102482 - Ordunez P, Lombardi C, Picone DS, Brady TM, Campbell NRC, Moran AE, et al. HEARTS in the Americas: A global example of using clinically validated automated blood pressure devices in cardiovascular disease prevention and management in primary health care settings. J Hum Hypertens. 2023;37(2):126–129. DOI: 10.1038/s41371-022-00659-z
- Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. on behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation. 2019;139:e840–e878. DOI: 10.1161/CIR.0000000000000664
- Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. American Heart Association. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation. 2023;148(20):1636–1664. DOI: 10.1161/CIR.0000000000001186
- PAHO. Better Care for NCDs: Accelerating Actions in Primary Health Care. [Internet]. Available at:
https://www.paho.org/en/documents/better-care-ncds-accelerating-actions-primary-health-care . (Access: 12 – Nov – 2024). - Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care. 1986;2(1):53–63. DOI: 10.1017/S0266462300002774
- Satheesh G, Dhurjati R, Huffman MD, Rosende A, Rodgers A, Prabhakaran D, et. al. Standardized treatment protocols for hypertension: Global availability, characteristics, and alignment with the hypertension guideline recommendations. J Hypertens. 2024;42(5):902–908. DOI: 10.1097/HJH.0000000000003636
- Ordunez P, Campbell NRC, Giraldo Arcila GP, Angell SY, Lombardi C, Brettler JW, et al. HEARTS in the Americas: Innovations for improving hypertension and cardiovascular disease risk management in primary care. Rev Panam Salud Publica. 2022;46:
e96 . PMID: 35855441; PMCID: PMC9288223. DOI: 10.26633/RPSP.2022.96 - Cheung AK, Whelton PK, Muntner P, Schutte AE, Moran AE, Williams B, et al. International consensus on standardized clinic blood pressure measurement – a call to action. Am J Med. 2023;136(5):438–445.e1. DOI: 10.1016/j.amjmed.2022.12.015
- Sharman JE, Ordunez P, Brady T, Parati G, Stergiou G, Whelton PK, et al. The urgency to regulate validation of automated blood pressure measuring devices: a policy statement and call to action from the world hypertension league. J Hum Hypertens. 2023;37(2):155–159. DOI: 10.1038/s41371-022-00747-0
- Whelton PK, Picone DS, Padwal R, Campbell NRC, Drawz P, Rakotz MK, et al. Global proliferation and clinical consequences of non-validated automated BP devices. J Hum Hypertens. 2023;37(2):115–119. DOI: 10.1038/s41371-022-00667-z
- Picone DS, Campbell NRC, Schutte AE, Olsen MH, Ordunez P, Whelton PK, et al. Validation status of blood pressure measuring devices sold globally. JAMA. 2022;327(7):680–681. DOI: 10.1001/jama.2021.24464
- Lombardi C, Picone DS, Sharman JE, Campbell NRC, Farias R, Guerre S, et al. Country experiences on the path to exclusive use of validated automated blood pressure measuring devices within the HEARTS in the Americas Initiative. J Hum Hypertens. 2023;37(2):120–125. Epub 2022 Jul 11. PMID: 35817799; PMCID: PMC9957722. DOI: 10.1038/s41371-022-00706-9
- Whelton PK, O’Connell S, Mills KT, He J. Optimal antihypertensive systolic blood pressure: A systematic review and meta-analysis. Hypertension. 2024;81(11):2329–2339. DOI: 10.1161/HYPERTENSIONAHA.124.23597
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314. DOI: 10.1016/j.kint.2023.10.018
- World Health Organization (September 19, 2023). Global report on hypertension: the race against a silent killer. [Internet]. Available at:
https://www.who.int/publications/i/item/9789240081062 - GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–234. DOI: 10.1016/S0140-6736(23)01301-6. Epub 2023 Jun 22. Erratum in: Lancet. 2023 Sep 30;402(10408):1132. DOI: https://doi.org/10.1016/S0140-6736(23)02044-5
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: A pooled analysis of 1101 population-representative studies with 82 million participants. Lancet. 2024;S0140-6736(24)02317-1. DOI: 10.1016/S0140-6736(24)02317-1
- Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. ESPRIT Collaborative Group. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245–255. DOI: 10.1016/S0140-6736(24)01028-6
- Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):559–569. DOI: 10.1016/j.kint.2020.10.026
- Jin Y, Wang K, Xiao B, Wang M, Gao X, Zhang J, et al. Global burden of atrial fibrillation/flutter due to high systolic blood pressure from 1990 to 2019: Estimates from the global burden of disease study 2019. J Clin Hypertens (Greenwich). 2022;24(11):1461–1472. DOI: 10.1111/jch.14584
- Dong XJ, Wang BB, Hou FF, Jiao Y, Li HW, Lv SP, et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2019. Europace. 2023;25(3):793–803. DOI: 10.1093/europace/euac237
- Welton NJ, McAleenan A, Thom HH, Davies P, Hollingworth W, Higgins JP, et al. Screening strategies for atrial fibrillation: A systematic review and cost-effectiveness analysis. Health Technol Assess. 2017;21(29):1–236. DOI: 10.3310/hta21290
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109–279. DOI: 10.1016/j.jacc.2023.08.017
- Freedman B, Hindricks G, Banerjee A, Baranchuk A, Ching CK, Du X, et al. World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. Glob Heart. 2021;16(1):41. DOI: 10.5334/gh.1023
- Niiranen T, Schnabel R, Schutte AE, Biton Y, Boriani G, Buckley C, et al. Hypertension and atrial fibrillation: A frontier Review from the AF-SCREEN International Collaboration. Circulation. 2025;151(12): 863–877. DOI: 10.1161/CIRCULATIONAHA.124.071047
- Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021;385(12):1067–1077. DOI: 10.1056/NEJMoa2105675
- Aminde LN, Nugraheni WP, Mubasyiroh R, Rachmawati T, Dwirahmadi F, Martini S, et al. Cost-effectiveness analysis of low-sodium potassium-rich salt substitutes in Indonesia: An equity modelling study. Lancet Reg Health Southeast Asia. 2024;26:100432. DOI: 10.1016/j.lansea.2024.100432
- Marklund M, Singh G, Greer R, Cudhea F, Matsushita K, Micha R, et al. Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: Modelling study. BMJ. 2020;369:
m824 . DOI: 10.1136/bmj.m824 - Bernabe-Ortiz A, Sal Y, Rosas VG, Ponce-Lucero V, Cárdenas MK, Carrillo-Larco RM, Diez-Canseco F, et al. Effect of salt substitution on community-wide blood pressure and hypertension incidence. Nat Med. 2020;26(3):374–378. DOI: 10.1038/s41591-020-0754-2
- Yuan Y, Jin A, Neal B, Feng X, Qiao Q, Wang H, et al. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: A cluster-randomized trial. Nat Med. 2023;29(4):973–981. DOI: 10.1038/s41591-023-02286-8
- Arsenijevic J, Groot W. Physical activity on prescription schemes (PARS): Do programme characteristics influence effectiveness? Results of a systematic review and meta-analyses. BMJ Open. 2017;7(2):
e012156 . DOI: 10.1136/bmjopen-2016-012156 - Patterson R, McNamara E, Tainio M, de Sá TH, Smith AD, Sharp SJ, et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: A systematic review and dose response meta-analysis. Eur J Epidemiol. 2018;33(9):811–829. DOI: 10.1007/s10654-018-0380-1
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381. DOI: 10.1093/eurheartj/ehw106
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646. DOI: 10.1161/CIR.0000000000000678
- Skotsimara G, Antonopoulos AS, Oikonomou E, Siasos G, Ioakeimidis N, Tsalamandris S, et al. Crdiovascular effects of electronic cigarettes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2019;26(11):1219–1228. DOI: 10.1177/2047487319832975
- Jeffers AM, Glantz S, Byers AL, Keyhani S. Association of cannabis use with cardiovascular outcomes among US adults. J Am Heart Assoc. 2024;13(5):
e030178 . Epub 2024 Feb 28. PMID: 38415581; PMCID: PMC10944074. DOI: 10.1161/JAHA.123.030178 - Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and safety of a novel low-dose triple single-pill combination compared with placebo for initial treatment of hypertension. J Am Coll Cardiol. 2024;84(24):2393–2403. DOI: 10.1016/j.jacc.2024.08.025
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–e115. DOI: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13. Erratum in: Hypertension. 2018 Jun;71(6):e140–e144. DOI: https://doi.org/10.1161/HYP.0000000000000076
- 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1–15. DOI: 10.1016/j.ejim.2024.05.033
- 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. DOI: 10.1093/eurheartj/ehae178
- WHO Model List of Essential Medicines – 23rd list, 2023. WHO/MHP/HPS/EML/2023.02. [Internet]. Available at:
https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02 - O’Hagan E, McIntyre D, Nguyen T, Tan KM, Hanlon P, Siddiqui M, et al. A cross-sectional survey of fixed-dose combination antihypertensive medicine prescribing in twenty-four countries, including qualitative insights. Glob Heart. 2024;19(1):73. DOI: 10.5334/gh.1353
- Souza KM, Giron N, Vallini J, Hallar K, Ordunez P, Rosende A, et al. Barriers to access to antihypertensive medicines: insights from the HEARTS initiative in Latin American and Caribbean region. J Pharm Policy Pract. 2024;17(1):
2379045 . DOI: 10.1080/20523211.2024.2379045 - McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol. 2021;6(2):148–158. DOI: 10.1001/jamacardio.2020.4511
- AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–3209. DOI: 10.1016/j.jacc.2018.11.002. Erratum in: J Am Coll Cardiol. 2019;73(24):3234–3237.
- PAHO Strategic Fund Product List. Aug. 2023. Available at:
https://www.paho.org/sites/default/files/strategic-fund-product-list-230821_0.pdf - Lasserson DS, Buclin T, Glasziou P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart. 2011;97(21):1771–1775. DOI: 10.1136/hrt.2010.221473
- Boima V, Doku A, Agyekum F, Tuglo LS, Agyemang C. Effectiveness of digital health interventions on blood pressure control, lifestyle behaviours and adherence to medication in patients with hypertension in low-income and middle-income countries: A systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2024;69:102432. DOI: 10.1016/j.eclinm.2024.102432
- He J, Ouyang N, Guo X, Sun G, Li Z, Mu J, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): An open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023;401(10380):928–938. DOI: 10.1016/S0140-6736(22)02603-4
- Giraldo GP, Joseph KT, Angell SY, Campbell NRC, Connell K, DiPette DJ, et al. Mapping stages, barriers and facilitators to the implementation of HEARTS in the Americas initiative in 12 countries: A qualitative study. J Clin Hypertens (Greenwich). 2021;23(4):755–765. DOI: 10.1111/jch.14157
- Schwalm JD, McCready T, Lopez-Jaramillo P, Yusoff K, Attaran A, Lamelas P, et al. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): A cluster-randomised controlled trial. Lancet. 2019;394(10205):1231–1242. DOI: 10.1016/S0140-6736(19)31949-X
- García-Zamora S, Pulido L. Vaccines in cardiology, an underutilized strategy to reduce the residual cardiovascular risk. Arch Peru Cardiol Cir Cardiovasc. 2024;5(1):29–39. DOI: 10.47487/apcyccv.v5i1.349
DOI: https://doi.org/10.5334/gh.1428 | Journal eISSN: 2211-8179
Language: English
Submitted on: Jan 29, 2025
Accepted on: May 2, 2025
Published on: May 27, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2025 Andres Rosende, Cesar Romero, Donald J. DiPette, Jeffrey Brettler, Patrick Van der Stuyft, Gautam Satheesh, Pablo Perel, Niamh Chapman, Andrew E. Moran, Aletta E. Schutte, James E. Sharman, Vilma Irazola, Mark D. Huffman, Norm R. C. Campbell, Abdul Salam, Fernando Lanas, Antonio Coca, Sebastian Garcia-Zamora, Alejandro Ferreiro, Patricio Lopez-Jaramillo, Jorge Rico-Fontalvo, Emily Ridley, Dean Picone, David Flood, Daniel José Piñeiro, Carolina Neira Ojeda, Gonzalo Rodriguez, Irmgardt A. Wellmann, Marcelo Orias, Marcela Rivera, Matías Villatoro Reyes, Oyere Onuma, Shaun Ramroop, Taskeen Khan, Yamile Valdes Gonzalez, Weimar Kunz Sebba Barroso, Frida L. Plavnik, Eric Zuniga, Ana María Grassani, Carlos Tajer, Ezequiel Zaidel, Marcos J. Marin, Shana Cyr-Philbert, Ignacio Amorin, Miguel Angel Diaz Aguilera, Luiz Bortolotto, Alvaro Avezum, Antonio Luiz P. Ribeiro, Sheldon Tobe, Teresa Aumala, Sonia Angell, Pablo Lavados, Sheila Ouriques Martins, Ana Munera Echeverri, Marc G. Jaffe, Dorairaj Prabhakaran, Gianfranco Parati, Xin Hua Zhang, Anthony Rodgers, Salim Yusuf, Paul K. Whelton, Pedro Ordunez, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.